Indian Generics Look To Benefit From Obama Administration
This article was originally published in PharmAsia News
Indian pharmaceutical makers expect to benefit from the change in administrations in the United States, with a new emphasis on support for generic drugs. India pharma insiders believe the Barack Obama administration will reform the health care system to make drugs more affordable and accessible, according to one analyst. That emphasis is seen as increasing generics use. India has more than 100 generics plants already approved by the U.S. FDA, he said, but noted the financial crisis would continue pressure to keep expenses down. (Click here for more
You may also be interested in...
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.